Flavonoid compounds may be prepared that are selective for certain cell organelles, and may be used as biological imaging agents. Organelles that may be imaged with flavonoid compounds include mitochondria and lysosomes. Advantageously, the flavonoids show specificity to certain organelles and may exhibit a florescence turn-on mechanism, where the flavonoids that have target an organelle exhibit a florescence response when excited.

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.

Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.

The present invention relates to compounds of Formula I, IA, II, IIA, III, or IIIA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

The present invention relates to compounds of Formula I, IA, II, IIA, III, or IIIA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

A compound of formula (I) for use in the prevention or treatment of a bacterial infection wherein: P.sup.X is selected from the group consisting of (P1), (P2) and (P3).

##STR00001##

The present invention is related to a new method for the synthesis of alpha-aminoalkylenephosphonic acid or its phosphonate esters comprising the steps of forming a reaction mixture by mixing a POP anhydride moiety comprising compound, having one P-atom at the oxidation state (+III) and the other P-atom at the oxidation state (+III) or (+V), an aminoalkanecarboxylic acid and an acid catalyst, wherein said reaction mixture comprises an equivalent ratio of alpha-aminoalkylene carboxylic acid to POP anhydride moieties of at least 0.2, and recovering the resulting alpha-aminoalkylene phosphonic acid compound or an ester thereof from the reaction mixture.

The present invention is related to a new method for the synthesis of alpha-aminoalkylenephosphonic acid or its phosphonate esters comprising the steps of forming a reaction mixture by mixing a POP anhydride moiety comprising compound, having one P-atom at the oxidation state (+III) and the other P-atom at the oxidation state (+III) or (+V), an aminoalkanecarboxylic acid and an acid catalyst, wherein said reaction mixture comprises an equivalent ratio of alpha-aminoalkylene carboxylic acid to POP anhydride moieties of at least 0.2, and recovering the resulting alpha-aminoalkylene phosphonic acid compound or an ester thereof from the reaction mixture.

N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, N.sup.2-phosphinyl amidinate metal salt complexes are described. Methods for making N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, and N.sup.2-phosphinyl amidinate metal salt complexes are also disclosed. Catalyst systems utilizing the N.sup.2-phosphinyl amidine metal salt complexes and N.sup.2-phosphinyl amidinate metal salt complexes are also disclosed along with the use of the N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, and N.sup.2-phosphinyl amidinate metal salt complexes for the oligomerization and/or polymerization of olefins.

N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, N.sup.2-phosphinyl amidinate metal salt complexes are described. Methods for making N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, and N.sup.2-phosphinyl amidinate metal salt complexes are also disclosed. Catalyst systems utilizing the N.sup.2-phosphinyl amidine metal salt complexes and N.sup.2-phosphinyl amidinate metal salt complexes are also disclosed along with the use of the N.sup.2-phosphinyl amidine compounds, N.sup.2-phosphinyl amidinates, N.sup.2-phosphinyl amidine metal salt complexes, and N.sup.2-phosphinyl amidinate metal salt complexes for the oligomerization and/or polymerization of olefins.